AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26618456
Drug: HYC-24L (Juvéderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYC-24L (Juvéderm Ultra XC, 24 mg/mL hyaluronic acid with 0.3% lidocaine)
Trial: 26618456
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, delayed treatment)
Trial: 19773024
Drug: Dietetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietetic treatment + cognitive therapy
Trial: 19773024
Drug: Dietetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietetic treatment + physical exercise
Trial: 30156866
Drug: Continuous Subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Subcutaneous Insulin Infusion (CSII)
Trial: 17357293
Drug: Continuous Intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Intravenous Insulin Infusion (IVII)
Trial: 16845252
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg daily
Trial: 1302160
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg + Lasix 20 mg daily
Trial: 1302160
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with ramipril
Trial: 3823619
Drug: Clofibate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate (500 mg t.i.d.)
Trial: 31542339
Drug: Intravitreal 2
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal 2 mg aflibercept every 4 weeks (monthly)
Trial: 31542339
Drug: Intravitreal 2
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal 2 mg aflibercept every 12 weeks (quarterly)
Trial: 24716820
Drug: Automated insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated insulin bolus advisor (EXP)
Trial: 20236381
Drug: PITA injections
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PITA injections
Trial: 20236381
Drug: No PITA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No PITA injections (Control)
Trial: 12475841
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL (5 mg) terbutaline + 2 mL of 3% saline solution (group 2)
Trial: 12475841
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL (5 mg) terbutaline + 2 mL of 0.9% saline solution (group 1)
Trial: 9804214
Drug: Chronic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic low dose r-HFSH (group A)
Trial: 7593449
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 mg, twice daily)
Trial: 2180831
Drug: CHO‐5 (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐5 (5.0 g/100 ml carbohydrate solution)
Trial: 2180831
Drug: CHO‐6 (6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐6 (6.0 g/100 ml carbohydrate solution)
Trial: 2180831
Drug: CHO‐7.5 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐7.5 (7.5 g/100 ml carbohydrate solution)
Trial: 6990215
Drug: Labetalol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (300 mg twice a day)
Trial: 9542480
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg twice a day)
Trial: 6990215
Drug: Hydrallazine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrallazine (50 mg twice a day)
Trial: 7967758
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no exercise prescription)
Trial: 11716166
Drug: nCPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP treatment (n=33)
Trial: 7926290
Drug: Insulin-resistant group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant group (SI: 0.31 +/‐ 0.06 x 10(‐4) min‐1.pmol/l‐1)
Trial: 7926290
Drug: Insulin-sensitive group
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-sensitive group (SI: 0.92 +/‐ 0.11 x 10(‐4) min‐1.pmol/l‐1)
Trial: 2686428
Drug: Ciprofloxacin, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 200 mg every 12 hours
Trial: 2686428
Drug: Ceftazidime, 2
RxNorm normalized name: CefTAZidime, 2 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime, 2 g every eight hours
Trial: 21119031
Drug: HER2-targeted agents
RxNorm normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HER2-targeted agents (trastuzumab and lapatinib) with standard treatment (taxanes, anthracyclines, capecitabine, anastrozole, letrozole)
Trial: 3103245
Drug: Cefotaxime (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (3 doses of 1 gram each at induction and 1 and 3 hours later)
Trial: 3103245
Drug: Cefamandole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (3 doses of 1 gram each at induction and 1 and 3 hours later)
Trial: 17471340
Drug: Mupirocin nasal
RxNorm normalized name: mupirocin Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin nasal ointment (twice daily for 5 days prior to surgery)
Trial: 12945073
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no mupirocin treatment)
Trial: 12542598
Drug: Terlipressin 1
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin 1 mg i.v. at 12‐h intervals (group A)
Trial: 10711411
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (4 IU/m2 per day, subcutaneous injections, every evening for 6 months)
Trial: 28960867
Drug: Digitalis therapy
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis therapy
Trial: 11852171
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory agents
Trial: 31170994
Drug: AITC cough
RxNorm normalized name: Pediaclear Cough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AITC cough challenge (selective TRPA1 agonist)
Trial: 31170994
Drug: Capsaicin cough
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin cough challenge (selective TRPV1 agonist)
Trial: 29106594
Drug: Estradiol therapy
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol therapy (n = 21)
Trial: 27041733
Drug: Pasireotide administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide administration after pancreatic resection
Trial: 22377745
Drug: Paroxetine 10
RxNorm normalized name: PARoxetine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 10 mg/d
Trial: 22377745
Drug: Paroxetine 10
RxNorm normalized name: PARoxetine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 10 mg/d and 20 mg/d
Trial: 19297314
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 on day 1
Trial: 19297314
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 on day 5 with oblimersen 7 mg/kg/day continuous i.v. infusion on days 1-7
Trial: 17697219
Drug: Fentanyl 10
RxNorm normalized name: FENTANYL 100MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 10 microg x ml(‐1) combined with prolonged injection (30 s) (Group IV)
Trial: 17697219
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 microg x ml(‐1) (Group I)
Trial: 17697219
Drug: Fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 25 microg x ml(‐1) (Group II)
Trial: 17697219
Drug: Fentanyl 10
RxNorm normalized name: FENTANYL 100MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 10 microg x ml(‐1) (Group III)
Trial: 9710871
Drug: Carbohydrate solution
RxNorm normalized name: phosphorated carbohydrate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate solution (0.7 g/kg BW/h)
Trial: 9710871
Drug: Carbohydrate solution
RxNorm normalized name: phosphorated carbohydrate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate solution plus caffeine (5 mg/kg BW)
Trial: 3056237
Drug: Ceftizoxime (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime (30 mg/kg)
Trial: 3056237
Drug: Cefoxitin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (30 mg/kg)
Trial: 4881068
Drug: Suramin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin 1.0 g, 0.5 g, and 0.25 g dosages
Trial: 28301561
Drug: 90-minute hatha
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-minute hatha yoga practice groups twice weekly for 8 weeks
Trial: 28301561
Drug: 90-minute attention
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-minute attention control education groups twice weekly for 8 weeks
Trial: 24519034
Drug: ACE- group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE- group (standard ISSNHL treatment regimen only)
Trial: 23754736
Drug: Sifalimumab administered
RxNorm normalized name: Sifalimumab
DrugBank: Sifalimumab (DB12773)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sifalimumab administered every 14 days as a 30- to 60-minute intravenous infusion with escalating doses of 0.3, 1.0, 3.0, and 10 mg/kg.
Trial: 23754736
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing of sifalimumab at 200, 600, and 1,200 mg monthly (with a loading dose at Day 14).
Trial: 9414336
Drug: Alternative keyboard
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative keyboard designs (e.g. split keyboard, laterally inclined halves)
Trial: 8466068
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of regular insulin (20 u) followed by a glucose infusion (500 ml 5% dextrose in water) over 15 min
Trial: 8466068
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of regular insulin (20 u)
Trial: 3082644
Drug: Fluvoxamine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine, 50 mg twice a day
Trial: 3082644
Drug: Mianserin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin, 20 mg twice a day
Trial: 31995130
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication alone
Trial: 29617064
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication with CGT
Trial: 26970401
Drug: Certified nurse‐midwife
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certified nurse‐midwife telephone‐administered interpersonal psychotherapy (CNM‐IPT) sessions (up to eight 50-minute sessions)
Trial: 25424297
Drug: Fentanyl (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (25 µg) combined with hyperbaric bupivacaine 0.5% (10mg)
Trial: 25424297
Drug: Sufentanil (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (5.0 µg) combined with hyperbaric bupivacaine 0.5% (10mg)
Trial: 12951862
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg, twice-weekly subcutaneous injections for 4 months)
Trial: 11121908
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg twice daily (EAC)
Trial: 11121908
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily (OAC)
Trial: 7645790
Drug: Midazolam (Versed),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (Versed), 0.4 mg/kg
Trial: 7645790
Drug: Ketamine (Ketalar),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (Ketalar), 3 mg/kg
Trial: 3099943
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir 800 mg five times daily for seven days
Trial: 31167867
Drug: Caseworker-delivered multicomponent
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caseworker-delivered multicomponent intervention (behavioural counselling, nicotine spray, referral to Quitline and primary care)
Trial: 23327023
Drug: Gargling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gargling with ketamine 40 mg in 30 ml saline for 60 seconds (Group K)
Trial: 23327023
Drug: 0.05% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% betamethasone gel applied over endotracheal tube (Group B)
Trial: 20874515
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg of H1N1 hemagglutinin vaccine
Trial: 15942235
Drug: Cloxacillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxacillin (2 g/day)
Trial: 15942235
Drug: Pristinamycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pristinamycin (2 g/day)
Trial: 10472877
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin (4.5 mU/minute initially, increased by 4.5 mU/minute every 30 minutes) for induction
Trial: 10472877
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin (1.5 mU/minute initially, increased by 1.5 mU/minute every 30 minutes) for induction
Trial: 10472877
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin for augmentation
Trial: 10472877
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin for augmentation
Trial: 10472877
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin for induction in nulliparous women
Trial: 10472877
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin for induction in nulliparous women
Trial: 10472877
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin for induction in nulliparous women (cephalopelvic disproportion)
Trial: 10472877
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin for induction in nulliparous women (cephalopelvic disproportion)
Trial: 6627821
Drug: Caffeine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (50 to 800 mg)
Trial: 6627821
Drug: d-Amphetamine sulfate
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine sulfate (25 mg)
Trial: 24418365
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for 18 months without bisphosphonates
Trial: 24418365
Drug: Shorter androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter androgen deprivation therapy (ADT) course combined with bisphosphonates
Trial: 20498212
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy
Trial: 23078756
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who lost drug free remission
Trial: 19324974
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg or 80 mg)
Trial: 12853502
Drug: Inhaled triamcinolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled triamcinolone, 1,200 microg daily
Trial: 8538705
Drug: Two-component acellular
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-component acellular DTP vaccine (2566 children)
Trial: 8538705
Drug: Five-component acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-component acellular DTP vaccine (2587 children)
Trial: 8538705
Drug: Whole-cell DTP
RxNorm normalized name: ActHIB with Whole-Cell DTP Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell DTP vaccine (2102 children)
Trial: 8538705
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (DT vaccine, 2574 children)
Trial: 2070378
Drug: NH4F treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NH4F treatment
Trial: 2070378
Drug: NaF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF treatment
Trial: 7055433
Drug: 12 hours
RxNorm normalized name: PATCH, TRANSDERMAL 12 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 hours of penicillin G potassium and doxycycline hyclate
Trial: 7055433
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of penicillin G potassium and doxycycline hyclate
Trial: 7055433
Drug: 12 hours
RxNorm normalized name: PATCH, TRANSDERMAL 12 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 hours and 5 days of antibiotics
Trial: 31782032
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy (two times four cycles)
Trial: 31782032
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy (eight subsequent cycles)
Trial: 20843608
Drug: Trier Social
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trier Social Stress Test for Groups (TSST-G)
Trial: 25985446
Drug: AI/2-CDA (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI/2-CDA (6 mg/m²/d, days 1, 3) in combination with cytarabine/idarubicin (AI=500 mg/m² cytarabine 5 days continuous infusion plus 7 mg/m²/d idarubicin, days 3 and 5)
Trial: 25985446
Drug: AI (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI (500 mg/m² cytarabine 5 days continuous infusion plus 7 mg/m²/d idarubicin, days 3 and 5)
Trial: 21735660
Drug: Integrated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated therapy of traditional Chinese and Western medicine
Trial: 21735660
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (transurethral plasmakentic vaporization, anti-infection, rehydration, and supportive therapies)
Trial: 19906345
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d memantine
Trial: 10507241
Drug: Amoxapine formulation
RxNorm normalized name: Amoxapine
DrugBank: Amoxapine (DB00543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxapine formulation 1
Trial: 10507241
Drug: Amoxapine formulation
RxNorm normalized name: Amoxapine
DrugBank: Amoxapine (DB00543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxapine formulation 2
Trial: 1755739
Drug: PhXA34 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhXA34 10 micrograms once daily for 7 days
Trial: 27106176
Drug: Lyophilisate formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilisate formulation
Trial: 27106176
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation
Trial: 23146788
Drug: Newly diagnosed
RxNorm normalized name: AUTOLOGOUS CD34+ CELLS ISOLATED FROM BONE MARROW OF NEWLY DIAGNOSED X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (X-SCID) PATIENTS, TRANSDUCED EX VIVO WITH A SELF-INACTIVATING LENTIVIRAL VECTOR, ENCODING CODON-OPTIMIZED HUMAN INTERLEUKIN-2 RECEPTOR SUBUNIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly diagnosed type 1 diabetes (DMT1) patients immediately after treatment of diabetic ketoacidosis (study I)
Trial: 17918321
Drug: Standard cardiotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cardiotropic therapy (nitrates, beta-blockers, ACE inhibitors on demand, diuretics, antioxidants) and placebo
Trial: 17918321
Drug: Standard cardiotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cardiotropic therapy plus impase (1 tablet every other day for 3 months)
Trial: 12018633
Drug: Intact parathyroid
RxNorm normalized name: Intact parathyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact parathyroid hormone (PTH) levels